American Society of Hematology. (2019).
FDA Approves Luspatercept-aamt for Anemia in Patients with Beta Thalassemia.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-luspatercept-aamt-for-anemia-in-patients-with-beta-thalassemia.
American Society of Hematology.
"FDA Approves Luspatercept-aamt for Anemia in Patients with Beta Thalassemia." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-luspatercept-aamt-for-anemia-in-patients-with-beta-thalassemia
(label-accessed April 20, 2024).
"American Society of Hematology."
FDA Approves Luspatercept-aamt for Anemia in Patients with Beta Thalassemia, 20 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-luspatercept-aamt-for-anemia-in-patients-with-beta-thalassemia.
